



**NAVISCAN ANNOUNCES NEW LICENSING AGREEMENT FOR  
PATENTED TECHNOLOGY**  
***Biopsy-Guidance Accessory the Latest Addition to Company's  
Intellectual Property Portfolio***

San Diego, CA - June 1, 2009 - Naviscan, Inc. announced that it has issued a non-exclusive licensing agreement with an undisclosed imaging company for intellectual property enabling Naviscan's Stereo Navigator<sup>®</sup> PEM-guided biopsy accessory. This is the second licensing agreement based on Naviscan's robust intellectual property portfolio and further validates Naviscan as the leader in Molecular Breast Imaging. The company is currently negotiating licensing agreements with diagnostic imaging companies and expects these agreements to be signed as early as the third quarter of 2009.

"This licensing agreement further validates the attractiveness of our patent portfolio to leading companies in the medical imaging sector," said Paul Mirabella, Chairman and CEO of Naviscan, Inc. "It also illustrates how we are leveraging our intellectual property and capitalizing on our innovative technology to create additional value to our share holders."

The new licensing agreement covers the use of Stereo Navigator<sup>®</sup> a medical method and apparatus for the localization and biopsy of lesions. This patent enables PET scanners and gamma cameras to obtain emission data, locate the abnormal tissue and process the data to best guide a biopsy needle to acquire a sample of the abnormal tissue. The previous licensing agreement concerned a method and apparatus patent enabling the immobilization and compression of a body part for the purposes of

**Naviscan, Inc.**

**Corporate Headquarters**  
6865 Flanders Dr. Suite B  
San Diego, CA 92121 USA  
Main: 858.587.3641  
Fax: 858.587.2596



collecting PET or gamma emission data in an effort to create a physiological image of the body part.

“Naviscan currently has four other patents pending,” continued Mirabella. “Our expanding patent portfolio continues to strengthen our technology leadership role while creating opportunities to build strategic partnerships, monetize our intellectual properties and, in turn, increase the company’s valuation.”

Naviscan was recently awarded Frost & Sullivan’s 2009 “Emerging Technology of the Year.” The company remains firmly committed to championing excellence in the diagnostic imaging industry and seeking creative solutions that benefit the physicians and patients it serves.

### **About Naviscan, Inc.**

Naviscan founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging, guide radiological and surgical procedures, and advance new clinical therapies. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. as well as utilized in clinical research studies, funded in part by the National Institutes of Health.

The Company is headquartered in San Diego, California and is the first company to obtain FDA clearance of a high-resolution PET scanner designed to image small body parts. For more information, call 1.858.587.3641 or visit [www.naviscan.com](http://www.naviscan.com)

### **Contact Information**

Guillaume Bailliard  
VP, Marketing  
Naviscan, Inc.  
Tel: (858) 332-0941  
[gbailliard@naviscan.com](mailto:gbailliard@naviscan.com)